The Malignant Mesothelioma Drug Pipeline Analysis highlights the evolving landscape of therapies targeting this aggressive cancer, primarily caused by asbestos exposure. With limited treatment options and poor prognosis, pharmaceutical companies are focusing on innovative drug candidates, including immune checkpoint inhibitors, tumor vaccines, and gene therapies. Advancements in immun... https://www.expertmarketresearch.com/clinical-trials/malignant-mesothelioma-drug-pipeline-insight